Abstract: Methods of making and osteoinductive compositions are provided. The method includes mixing isolated periosteum tissue with a demineralized bone matrix to form the osteoinductive composition. The periosteum tissue is isolated from the surface of large bones such as femur, tibia, humerus or a mixture thereof. The demineralized bone matrix can include a plurality of surface demineralized or fully demineralized bone fibers, bone chips, bone particles or mixtures thereof In the osteoinductive composition the substantially isolated periosteum tissue is from about 0.5% wt. to about 10% wt. A method for repairing a bone defect is also provided. The method of treatment includes applying to the bone defect a substantially effective amount of a mixture of isolated periosteum tissue and demineralized bone matrix.

Abstract: Bone implant compositions and methods are provide that have an outer surface, the outer surface comprising demineralized bone and having a cavity disposed in the outer surface, the cavity having a demineralized bone material coated therein; and an inner surface of the bone implant comprising cortical bone, the inner surface contacting the outer surface. The bone implant compositions and methods provided are osteoinductive and allow rapid bone fusion.

Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine and a gamma-aminobutyric acid compound at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.

Abstract: Bone implant compositions are provided that include a body made of cortical bone extending along an axis between a first end and a second end. The body includes an outer surface configured to engage host bone of a patient and at least one recess extending transverse to the axis into the outer surface of the body configured for disposal of an insert. At least one insert made of demineralized bone is disposed in the at least one recess.

Abstract: The invention provides compositions, kits, and methods for treatment of neuronal injury. In one embodiment, the composition comprises a biomembrane sealing agent, such as PEG, and a bioactive agent, such as a magnesium compound. The biomembrane sealing agent and/or the bioactive agent an intravenous administration, an intramuscular administration, an intrathecal administration, a subcutaneous administration, an epidural administration, a parenteral administration, a direct application onto or adjacent to a site of the pathological condition, and any combinations thereof. Alternatively, the biomembrane sealing agent and/or the bioactive agent may be delivered from a pump or an implant.

Abstract: A bone void filler material is provided for sustained release of a therapeutic agent. The bone void filler material comprising a biodegradable matrix having ceramic cement beads comprising calcium sulfate, and ceramic particles disposed within the matrix. The ceramic cement beads are loaded with the therapeutic agent to cause sustained release of the therapeutic agent. Methods of use are also disclosed.

Abstract: Described is a medically useful article comprising a three-dimensional body including one or more implantable substances, wherein the body defines one or more reservoirs for receiving amounts of a biocompatible wetting liquid. In certain embodiments the body is disruptable upon wetting with the biocompatible liquid to form a conformable implantable material such as a putty, paste or more flowable wetted implant material. Also described are methods for manufacturing such medical materials, and methods for using such medical materials to treat patients.

Abstract: Methods of making and osteoinductive compositions are provided. The method includes mixing isolated periosteum tissue with a demineralized bone matrix to form the osteoinductive composition. The periosteum tissue is isolated from the surface of large bones such as femur, tibia, humerus or a mixture thereof. The demineralized bone matrix can include a plurality of surface demineralized or fully demineralized bone fibers, bone chips, bone particles or mixtures thereof. In the osteoinductive composition the substantially isolated periosteum tissue is from about 0.5% wt. to about 10% wt. A method for repairing a bone defect is also provided. The method of treatment includes applying to the bone defect a substantially effective amount of a mixture of isolated periosteum tissue and demineralized bone matrix.

Abstract: Pharmaceutical gels and methods for delivering a therapeutic agent to a target tissue site beneath the skin of a patient are provided, the gel being capable of adhering to the target tissue site and comprising one or more biodegradable depots containing an effective amount of the therapeutic agent. In various embodiments, the gel is sprayable and hardens after contacting the target tissue site.

Abstract: A bone void filler material is provided for sustained release of a therapeutic agent. The bone void filler material comprising a biodegradable matrix having ceramic cement beads comprising calcium sulfate, and ceramic particles disposed within the matrix. The ceramic cement beads are loaded with the therapeutic agent to cause sustained release of the therapeutic agent. Methods of use are also disclosed.

Abstract: The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a therapeutically effective amount of clonidine or pharmaceutically acceptable salt thereof and a polymer; wherein the depot is implantable at a site beneath the skin to reduce, prevent or treat post-operative pain, and the depot is capable of releasing (i) about 5% to about 45% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a first period of up to 48 hours and (ii) about 55% to about 95% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a subsequent period of at least 3 days.

Abstract: A composite interbody bone implant device is provided including a body having a non-bone composition, such as a polymer, formed into a shape and including one or more cavities. An osteoinductive material, such as bone allograft tissue, may be retained in the one or more cavities of the body. The body is formable via injection molding and/or machining into a shape and size adapted for implantation at a surgical site. The dimensions of the body include a length, a width and a thickness, and the thickness of the body may be less than at least one of the length and width.

Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.

Abstract: Effective treatments of pain and inflammation are provided. Through the administration of an effective amount of fluocinolone at or near a target site, one can reduce, prevent or treat inflammation and pain and autoimmune disorders. In various embodiments, fluocinolone formulations may be provided within biodegradable polymers to reduce, prevent or treat sciatic pain and/or inflammation. In various embodiments, prevent transplant rejection for at least twenty-five days. In some embodiments, the pain relief can be for at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.

Abstract: The invention provides methods and composition developed to be used with imaging techniques and useful for diagnosis and monitoring the pain generator(s) of axial pain with or without radiculopathy and methods for screening therapeutic compounds potentially useful for treating axial pain with or without radiculopathy. Alternatively, degenerated discs can be monitored and treated before occurrence of a pathological pain condition. Pain markers and markers of degeneration include markers of neuronal, vascular, immune and matrix elements.

Abstract: A delivery system comprising a covering having at least two compartments is provided. A first compartment contains a first therapeutic agent and the second compartment can be unfilled and is configured to receive a second therapeutic agent. The first compartment and the second compartment are separated by at least one removable separation member, for example a drawstring, that can be pulled to allow the first and second therapeutic agents to mix prior to delivery at a selected surgical site. Either the first or second compartment of the covering define an opening further comprising a pre-attached sealing member, which can be a flap sealable by heat, sutures, pressing or interference fittings. The opening of the empty compartment can be configured to receive a filling member, such as a funnel fitted with a spring loaded clip for temporary attachment to the covering. A method of treating a bone defect in a patient utilizing the delivery system is also provided.

Abstract: Flowable compositions and methods are provided for delivering a therapeutic agent at or near a target tissue site beneath the skin of a patient, the flowable composition comprising (i) a solvent and (ii) an effective amount of the therapeutic agent, the flowable composition being capable of hardening to form a drug depot at a physiological temperature or as solvent contacts bodily fluid at or near the target tissue site, wherein the drug depot is capable of releasing the therapeutic agent over a period of at least one day and the target tissue site comprises at least one muscle, ligament, tendon, cartilage, spinal disc, spinal foraminal space near the spinal nerve root, facet or synovial joint, or spinal canal.

Abstract: A composite interbody bone implant device is provided including a body having a non-bone composition, such as a polymer, formed into a shape and including one or more cavities. An osteoinductive material, such as bone allograft tissue, may be retained in the one or more cavities of the body. The body is formable via injection molding and/or machining into a shape and size adapted for implantation at a surgical site. The dimensions of the body include a length, a width and a thickness, and the thickness of the body may be less than at least one of the length and width.

Abstract: Described are implantable, malleable medical materials comprising mineral particles, insoluble collagen fibers, and a gel-forming polysaccharide component and/or another added gel-former. The malleable medical materials can be used treat bone or other tissue defects in patients, including in conjunction with biologically active factors such as osteogenic proteins. Also described are methods and materials that can be used to prepare the malleable medical materials.

Abstract: The invention provides methods and composition developed to be used with imaging techniques and useful for diagnosis and monitoring the pain generator(s) of axial pain with or without radiculopathy and methods for screening therapeutic compounds potentially useful for treating axial pain with or without radiculopathy. Alternatively, degenerated discs can be monitored and treated before occurrence of a pathological pain condition. Pain markers and markers of degeneration include markers of neuronal, vascular, immune and matrix elements.